RGNX Stock Summary and Trading Ideas (Regenxbio | NASDAQ:RGNX)

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Regenxbio trades on the NASDAQ stock market under the symbol RGNX.

As of March 30, 2026, RGNX stock price declined to $7.75 with 84,447 million shares trading.

RGNX has a beta of 2.39, meaning it tends to be more sensitive to market movements. RGNX has a correlation of 0.23 to the broad based SPY ETF.

RGNX has a market cap of $392.33 million. This is considered a Small Cap stock.

Last quarter Regenxbio reported $30 million in Revenue and -$1.30 earnings per share. This fell short of revenue expectation by $-10 million and missed earnings estimates by -$.39.

In the last 3 years, RGNX traded as high as $28.80 and as low as $5.04.

The top ETF exchange traded funds that RGNX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

RGNX has underperformed the market in the last year with a price return of -2.0% while the SPY ETF gained +13.5%. RGNX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.3% and -9.6%, respectively, while the SPY returned -7.6% and -3.7%, respectively.

RGNX support price is $7.37 and resistance is $8.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGNX shares will trade within this expected range on the day.